Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Part 8. Rationale for SGLT2 Inhibitors Inhibit glucose reabsorption in the renal proximal tubule Resultant glucosuria leads to a decline in plasma glucose.

Advertisements

Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P

Part 1 of 4. Program Editors Ralph Anthony DeFronzo, MD Professor of Medicine and Chief of the Diabetes Division University of Texas Health Science Center.

Glucose tolerance testing. A

Copyright © 2017 American Academy of Pediatrics.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Nat. Rev. Cardiol. doi: /nrcardio

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

with undiagnosed diabetes mellitus by three diagnostic criteria

Figure 6 Differences in glycaemic control with the study drug

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.

Figure 1 Role of the kidney in glucose homeostasis

Figure 4 Effect of dapagliflozin on HbA1c and body weight

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Evidence for the incretin effect and

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 Glucose handling by the kidney

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Nat. Rev. Endocrinol. doi: /nrendo

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Figure 1 Acute kidney injury and chronic kidney disease

filtration rate (GFR), and sodium (Na+) excretion

Nat. Rev. Nephrol. doi: /nrneph

cardiovascular and renal systems

Joaquim Calado, René Santer, José Rueff Kidney International

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 The relationship between health fitness and pathogen load

James F. List, Jean M. Whaley Kidney International

Nat. Rev. Nephrol. doi: /nrneph

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Adapted with permission from Tesfaye, S. , Boulton, A. J

Nat. Rev. Nephrol. doi: /nrneph

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Figure 1 Patient, facility, health-care system and industry factors

Nat. Rev. Cardiol. doi: /nrcardio

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Correlation between plasma C reactive protein (CRP) and angiopoietin-like protein 4 (ANGPTL4). Correlation between plasma C reactive protein (CRP) and.

The results of the influenza vaccination measured by hemagglutination inhibition assay (HIA) among healthy elderly and elderly patients with type 2 diabetes.

Completed and ongoing CVOTs (6–14,39,44–58)

Overview of the actions of SGLT2, including the role of SGLT2 in glucose reabsorption in the proximal tubule (A) and sites of action at which SGLT2 inhibitors.

Age, cytomegalovirus (CMV) seropositivity in the healthy and type 2 diabetes mellitus (T2DM) and the response to influenza vaccination after the CMV serostatus.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Plasma angiopoietin-like protein 4 (ANGPTL4) in healthy controls (Controls), patients with metabolic syndrome without (MetS−I) and with low-grade inflammation.

Insulin secretion/insulin resistance (disposition) index (ΔINS/ΔGLU ÷ IR) in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT),

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

SGLT 2 transporter mRNA (left) and protein (middle) and glucose transport (α-methyl-d-glucopyranoside) (right) are increased in cultured renal proximal.

Glucose reabsorption in the kidney.

Effect of 4 weeks of an intensive exercise program on vaspin serum concentrations in normal glucose tolerant (NGT) individuals and patients with IGT or.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

RBP4 and glucose metabolism.

Plasma glucose (A), serum insulin (B), serum C peptide (C) and plasma GLP-1 level (D) during the 2-hour OGTT among subjects with normal glucose tolerance.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.170 Figure 3 Effect of dapagliflozin on maximum renal glucose reabsorption (TmG) and glucose threshold Figure 3 | Effect of dapagliflozin on maximum renal glucose reabsorption (TmG) and glucose threshold. a | In individuals with type 2 diabetes mellitus (T2DM) the TmG is significantly increased in normal glucose tolerant (NGT) individuals and similarly reduced by dapagliflozin in both groups. b | In patients with T2DM the renal threshold for glucose spillage is significantly increased compared to NGT individuals and reduced to less than 2.2 mmol/l (40 mg/dl) in both groups following dapagliflozin treatment. This effect explains why SGLT2 inhibitors produce marked glucosuria in non-diabetic individuals with a normal fasting plasma glucose concentration. Modified with permission from DeFronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169–3176 (2013). Copyright and all rights reserved. Material from this publication has been used with the permission of the American Diabetes Association. Modified with permission from DeFronzo, R. A. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36, 3169–3176 (2013). Copyright and all rights reserved. Material from this publication has been used with the permission of the American Diabetes Association. DeFronzo, R. A. et al. (2016) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.170